Bronchopulmonary dysplasia (BPD) is the leading cause of longterm respiratory disability among prematurely born infants and is a significant contributor to life-long neurodevelopmental problems. Affected infants are often exposed to a myriad of pharmacologic agents. In the neonatal intensive care unit. Many of these drugs are off label and have limited efficacy and significant toxicity. They include diuretics, bronchodilators, and agents to treat presumed gastro-esophageal reflux. This presentation will summarize the pulmonary injury sequence and the epidemiology of BPD. Various pharmacologic agents will be reviewed and evidence will be presented to balance their efficacy and safety. The presentation will conclude with a glimpse into evolving treatments
Steven M. Donn, MD, FAAP, FAARC is a Professor Emeritus of Pediatrics at the University of Michigan Medical School in Ann Arbor, where he is a member of the Division of Neonatal-Perinatal Medicine at C.S. Mott Children’s Hospital. He is certified by the American Board of Pediatrics and its Sub-board of Neonatal-Perinatal Medicine. Dr. Donn is actively involved in teaching, writing, editing, and clinical research. He is a member of numerous professional societies and is internationally known for his expertise in the management of respiratory failure in newborns. In 2020 he was named a Fellow of the American Association for Respiratory Care for his profound and lasting contribution to the profession of respiratory care. He has authored more than 240 medical journal articles, written or edited 37 books and specialty journals, and contributed 259 book chapters. Dr. Donn’s extracurricular interests include astronomy, international travel, photography, and spectator sports (Go Blue!).